Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Genzyme and Veracyte Announce Expanded U.S. Availability of the Afirma® Thyroid FNA Analysis for Improved Thyroid Nodule Diagnosis
Genzyme and Veracyte Announce Expanded U.S. Availability of the Afirma® Thyroid FNA Analysis for Improved Thyroid Nodule Diagnosis Cambridge, Mass. and South San Francisco, Calif. --- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY ), and Veracyte, Inc., a molecular diagnostics company
View HTML
Toggle Summary Richard T. Kloos, MD, Joins Veracyte as Senior Medical Director
Richard T. Kloos, MD, Joins Veracyte as Senior Medical Director South San Francisco, Calif. --- April 5, 2012 --- Veracyte, Inc. , a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced the appointment of Richard T.
View HTML
Toggle Summary Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients
Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients Cambridge, Mass. and South San Francisco, Calif. --- January 20, 2012 --- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) and one of the world’s leading biotechnology companies,
View HTML
Toggle Summary Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis
Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis South San Francisco, Calif. --- January 9, 2012 --- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that
View HTML
Toggle Summary New Data Suggest Veracyte’s Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results
New Data Suggest Veracyte’s Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results South San Francisco, Calif. --- September 1, 2011 --- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today
View HTML
Toggle Summary New Data Suggest Veracyte's Molecular Test Improves Accuracy of Thyroid Nodule Diagnosis Using Fine Needle Aspirate (FNA) Samples
New Data Suggest Veracyte's Molecular Test Improves Accuracy of Thyroid Nodule Diagnosis Using Fine Needle Aspirate (FNA) Samples South San Francisco, Calif.--- PRNewswire ---Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, announced that initial
View HTML
Toggle Summary Veracyte Completes $28 Million Series B Round – One Step Closer to Commercializing First Molecular Diagnostic Product
Veracyte Completes $28 Million Series B Round – One Step Closer to Commercializing First Molecular Diagnostic Product SOUTH SAN FRANCISCO, Calif.--- BUSINESS WIRE ---Veracyte, Inc. announced today the successful completion of its Series B round, a key milestone toward the company’s first product
View HTML